

An assessment of rates and covariates of mpox diagnosis and vaccination provides evidence to refine eligibility criteria for mpox vaccination among gay, bisexual and other men who have sex with men in the Netherlands

Philippe C.G. Adam (<https://orcid.org/0000-0002-8979-7372>)^{1,2,3}, Eline L.M. Op de Coul (<https://orcid.org/0000-0002-8263-9187>)⁴, Paul Zantkuijl (<https://orcid.org/0000000328388767>)⁵, Maria Xiridou (<https://orcid.org/0000-0002-5257-4503>)⁴, Hanna Bos⁵, Cor Blom⁵, Itsada Ketsuwan³, Margreet J.M. te Wierik⁴, Silke David⁴, John B.F. de Wit (<https://orcid.org/0000-0002-5895-7935>)⁶

1. Centre for Social Research in Health, UNSW Sydney, Sydney, Australia
2. Institute for Prevention and Social Research (IPSR Utrecht), Utrecht, the Netherlands
3. IPSR Bangkok, Bangkok, Thailand
4. National Institute for Public Health and the Environment, Bilthoven, the Netherlands
5. Soa Aids Nederland, Amsterdam, the Netherlands
6. Utrecht University, Department of Interdisciplinary Social Science, Utrecht, the Netherlands

5,131 words (main text), 6 tables, 0 figures

*** Correspondence:**

John B.F. de Wit

j.dewit@uu.nl

Abstract

Background: The 2022 multicountry mpox outbreaks predominantly affected gay, bisexual and other men who have sex with men (GBMSM) in non-endemic countries, including the Netherlands. We conducted a survey-based assessment of the alignment between the risk factors associated with mpox diagnosis among GBMSM in the Netherlands and the eligibility criteria used in 2022 for vaccinating this group, with the aim to refine these criteria.

Methods: An online self-report survey was conducted among adult GBMSM in the Netherlands between 29 July and 30 August 30, 2022, corresponding to the first month of the Dutch mpox vaccination campaign. GBMSM were recruited via advertisements on social media and gay dating apps. Participants reported on their sexual behaviour, mpox diagnosis, and/or (initial) mpox vaccination since the start of the outbreak. Covariables of mpox diagnosis and vaccination were assessed using logistic regression analyses.

Results: Of the 2,460 participants, 73 (3.0%, 95% CI 2.3%-3.6%) were diagnosed with mpox and 485 (19.7%, 95% CI 18.1%-21.3%) had received (initial) mpox vaccination. Using sample weighting, we estimated that, of the GBMSM population aged 18-80 years in the Netherlands, 1.1% (95% CI 0.7%-1.6%) had been diagnosed with mpox and 7.8% (95% CI 6.8%-8.9%) had received (initial) vaccination. HIV-PrEP use, living with HIV, reporting 20 or more sex partners in the past 12 months, and sex in sex venues/parties in the past 2 months were independent risk factors for mpox diagnosis. Except for sex in sex venues/parties, these variables were also independently associated with mpox vaccination.

Conclusion: This study provides novel evidence regarding the degree to which eligibility criteria for mpox vaccination align with the risk factors for mpox among GBMSM in the Netherlands. The findings contribute to a refinement of the eligibility criteria for mpox vaccination, to which sex in sex venues/parties should be added.

Keywords: mpox; monkeypox; MPXV infection; mpox vaccination; risk factors; gay, bisexual and other men who have sex with men (GBMSM); the Netherlands

Introduction

Mpox (formerly named monkeypox [1]), is a zoonotic infection caused by the monkeypox virus (MPXV) [2], that is endemic in parts of West and Central Africa [3]. With an estimated global total of about 30,000 cases in humans until 2019, its occurrence was considered rare until early 2022 [4]. Following initial reports of unusual cases in the United Kingdom in early May 2022 [5], multicountry outbreaks of human-to-human transmission of mpox have been identified in other non-endemic regions, including in Europe [6,7]. Between 1 January 2022 and 18 February 2023, 86,019 laboratory confirmed cases of mpox from 110 countries were reported to the World Health Organization (WHO) [8]. The 2022 mpox outbreaks predominantly occurred in gay, bisexual and other men who have sex with men (GBMSM) and likely resulted from transmission during sexual contact, making individuals with a higher number of sex partners and/or participating in specific sexual networks more susceptible to mpox [9,10, 11].

Observational studies suggest that smallpox vaccination attenuates mpox disease severity and acquisition risk [2,3,12], and WHO recommends primary prevention vaccination of individuals at high risk, notably GBMSM with multiple sexual partners [13]. However, as in other countries [14], the vaccine for mpox prevention is part of the strategic stockpile and was previously not available to the public in the Netherlands. This limited supply of vaccine necessitates the prioritisation of vaccination to population groups at highest risk [15]. The optimal allocation of vaccine requires an alignment of eligibility criteria for vaccination with risk factors for mpox, knowledge of which was limited when mpox vaccination programs were initiated. Based on data from the Netherlands until the end of August 2022, this study provides new evidence on risk factors related to mpox diagnosis among GBMSM and

assesses to what extent eligibility criteria for mpox vaccination are aligned with risk factors for mpox diagnosis.

The Netherlands is one of the European countries most affected by the mpox outbreak [7]. As of 16 February 2023, there were 1,261 confirmed cases of mpox in the Netherlands [16], a country with nearly 18 million inhabitants [17]. The first mpox case in the Netherlands was reported on 20 May 2022, and the number of new diagnoses peaked at the beginning of July 2022. After that time, the number of new diagnoses decreased and became sporadic as of mid-September 2022 [16]. In the second half of 2022, the number of mpox cases declined in the Netherlands [16], as well as in Europe [18] and globally [8]. Future trends in mpox infections remain uncertain, although new outbreaks are likely to be of smaller magnitude than the 2022 outbreak [19,20]. In this context, mpox remains a public health concern, and achieving and sustaining elimination are priorities [21].

The early mpox response in the Netherlands aimed at halting transmission and consisted of identifying infected people and implementing public health protection measures, including isolation, contact tracing and post-exposure prophylaxis (PEP) vaccination [11]. Awareness campaigns were also conducted among GBMSM. The stepwise roll-out of a centralised pre-exposure prophylaxis mpox vaccination program, using 32,000 doses of Imvanex® third generation smallpox vaccine, was initiated on 25 July 2022 [22]. The vaccination program made use of initial information on the characteristics of individuals diagnosed with mpox [11] to prioritise which GBMSM would (first) receive mpox vaccination.

General eligibility criteria for mpox vaccination were defined during meetings of the mpox expert council [23] and further specified for practical program implementation from available

data on risk indicators routinely recorded in PrEP, HIV and STI programs. This resulted in practical eligibility criteria for mpox vaccination for GBMSM and transgender persons encompassing: 1) prescribed HIV-PrEP at a sexual health centre (SHC) or by a general practitioner (GP), or registered on a waiting list for HIV-PrEP at a SHC; 2) living with HIV and receiving regular HCV screening as a proxy for high risk behaviour; or 3) having attended a SHC in the past six months because of 3a) partner notification related to HIV or STI, 3b) prior diagnosis of syphilis, gonorrhoea or chlamydia, or 3c) having had more than three partners in the past six months [22].

High-risk individuals eligible for vaccination were identified by the National Institute for Public Health and the Environment (RIVM) from the national surveillance database (SOAP) that includes information pertaining to all visits to SHCs, encompassing anonymised data on age, sex, (sexual) behaviour, STI diagnoses, HIV status, and use of HIV-PrEP (M. Haverkate, personal communication, 6 July 2023). From these data, lists of individuals eligible for vaccination were provided to each SHC by region. For persons receiving HIV-PrEP from their GP, GPs were contacted by the Public Health Services (PHS) in their region to invite eligible patients for vaccination. Similarly, the HIV healthcare providers of people living with HIV were asked by the PHS to invite eligible patients for vaccination. All eligible individuals identified received an invitation to vaccinate against mpox.

To gather comprehensive information on vaccination among individuals most at risk for mpox, we conducted an online survey among adult GBMSM in the Netherlands. Drawing on the survey data, we examined the proportions of GBMSM reporting mpox diagnoses and mpox vaccination, and the associations of mpox diagnosis and mpox vaccination with a range of potential risk factors. These factors encompassed the use of HIV-PrEP, living with HIV,

prior STI diagnosis, number of sex partners, and engagement in group sex, chemsex, and sex in gay saunas, sex clubs or at sex parties. We compared the factors associated with mpox diagnosis and mpox vaccination to evaluate the degree of alignment between the risk factors for mpox, the eligibility criteria for mpox vaccination, and the factors associated with mpox vaccination in various groups of GBMSM. Furthermore, we estimated the proportion of GBMSM reporting one or more risk factors for mpox, and estimated the level of immunity towards mpox achieved within this group due to mpox diagnosis, mpox vaccination or prior smallpox vaccination. In addition to providing novel evidence on the risk factors for mpox among GBMSM, the study findings contribute to guiding the targeting the mpox vaccination program in the Netherlands to GBMSM most at risk.

Materials and Methods

Design and procedures

A new, purposive cross-sectional self-report survey entitled *Monkeypox: a new challenge for your sex life* was conducted online among GBMSM in the Netherlands between 29 July and 30 August 2022. Participants were recruited via ads appropriate for the GBMSM population of interest on social media (i.e., Facebook and Instagram), gay dating sites and apps (i.e., Grindr and Recon), and *Man tot Man* the principal sexual health promotion platform for GBMSM in the Netherlands (<https://www.mantotman.nl/en>). The ads provided a link to a web page with information about the study. People were eligible to participate if they: lived in the Netherlands, were 18 years or older, identified as male (or non-binary or transgender) and ever had sex with a man. All participants provided informed consent and received no compensation. Ethics approval for this study was granted on 25 July 2022 by the Faculty Research Ethics Board of the Faculty of Social and Behavioural Sciences, Utrecht University, the Netherlands (reference number: 22-0358).

Measures

Participant characteristics: age (continuous in years and in five age ranges: 18–29 years, 30–39 years, 40–49 years, 50–59 years, and 60 or more years), education (tertiary education completed or ongoing, no/yes), province of residence (recoded as the Randstad metropolitan area, no/yes, that is, the main urban area of Netherlands encompassing the four largest cities, their suburbs and towns in between), sexual orientation (gay, bisexual, heterosexual, unsure). *Sexual behaviours:* number of male sex partners in the past 12 months (0, 1–9, 10–19, 20–49, 50–99, 100 or more; recoded as 0–9, 10–19, 20 or more), group sex (sex with two or more partners at the same time) in the past two months (no/yes), chemsex (the intentional use of drugs to enhance sex) in the past two months (no/yes), sex in a gay sauna, sex club or at a sex party (for brevity also referred to as sex venues or parties) in the past two months (no/yes). *HIV/STI-related indicators:* current HIV-PrEP use (no/yes), living with HIV (no/yes), STI diagnosis in the past 12 months (no/yes).

Mpox-related indicators: mpox diagnosis (no/yes), invitation received to vaccinate against mpox (no/yes), and having received (initial) mpox vaccination since the start of the 2022 outbreak (no/yes). Participants were not asked about the specific number of vaccine doses they had received. However, it is likely that the participants reporting mpox vaccination in this survey had only received one dose of the mpox vaccine. This is because the survey was conducted during the first month of the mpox vaccination campaign and the recommended interval between the first and second doses is at least four weeks [16].

Data analysis

Only eligible participants who fully completed the questionnaire were retained in the analyses presented in this paper. All analyses were conducted using SPSS (version 28).

Descriptive statistics were computed to describe the characteristics of the sample. Due to a lack of data regarding the characteristics of the GBMSM population in the Netherlands, it was not possible to evaluate the sample's representativeness with confidence. Nonetheless, it was clear from a comparison with national records [24] that the sample overrepresented GBMSM who use HIV-PrEP or live with HIV. A proportional weighting procedure was therefore applied to the data to redress the overrepresentation of GBMSM using HIV-PrEP or living with HIV. Sample weights were calculated based on data from national records showing that 11,576 GBMSM nationally used HIV-PrEP, and 13,289 GBMSM were in HIV care in 2022 [24]. The size of the sexually active GBMSM population aged 18-80 years living in the Netherlands was estimated at 310,000, based on an update of a previous estimate [25]. Our update was guided by social science research data regarding same-sex attraction and behaviour as well as gay and bisexual identity in the Netherlands [26]. We also accounted for the growth of the general population of the Netherlands [27]. Details of the study population size estimation are described in the Supplemental materials.

The proportional weighting procedure kept the sample size constant compared to the unweighted sample. Per convention, numbers are only reported for the unweighted data. To assess the impact of the weighting procedure on the sample characteristics, we calculated differences in percentages between unweighted and weighted estimates and computed the ratio of the two estimates.

Descriptive statistics were also calculated to estimate the proportions of participants (and 95% confidence intervals [CI]) reporting mpox diagnosis or mpox vaccination using both unweighted and weighted data. Univariable and multivariable logistic regression analyses

were used to identify the covariables associated with mpox diagnosis or mpox vaccination. The selected set of covariables included in the models encompassed both the general and specific eligibility criteria for vaccination used in the Netherlands (see Table 1). Additional sexual behaviours were also included that may be related to the transmission of MPXV but were not listed as eligibility criteria for mpox vaccination in the Netherlands in 2022 . In total, seven potential covariables were assessed: current use of HIV-PrEP, living with HIV, STI diagnosis in the past 12 months, number of sex partners in the past 12 months, group sex in the past two months, chemsex in the past two months, and sex in sex venues or parties in the past two months. Except for living with HIV, all these potential covariables were also suggested as possible risk factors for mpox by ECDC [28]. A backward elimination procedure was employed in the multivariable regression models to retain only the significantly associated covariables. Covariable analyses were conducted on unweighted data, as potential covariables were used for data weighting. Odds ratios and adjusted odds ratios, along with their corresponding 95% CIs and p-values, were calculated for univariable and multivariable analyses. Additionally, Nagelkerke R-squared values were calculated as an approximation of the proportion of variation in the dependent variable that can be explained by the independent variables in a logistic regression model.

The proportion of participants reporting one or more independent risk factors (IRFs) for mpox diagnosis, along with their 95% CIs, was calculated in the unweighted and weighted samples. Additional analyses were conducted to estimate the proportions of participants reporting specific numbers of IRFs, including one, two or three. The cumulative number of IRFs ranged from zero to three instead of four, as two of the four IRFs, namely current HIV-PrEP use and living with HIV, are mutually exclusive.

We estimated the proportion of individuals with immunity towards mpox due to previous mpox diagnosis, smallpox and mpox vaccination among participants with any independent risk factors for mpox. All participants diagnosed with mpox were considered to have achieved satisfactory immunity. Immunity through vaccination was also considered to be satisfactory if participants received two recent doses of the mpox vaccine. Note, however, that this was unlikely amongst participants as the survey was undertaken in the first month of the mpox vaccination program in the Netherlands. Immunity was also assumed to be satisfactory if participants received one dose of the mpox vaccine and had previously been vaccinated through the historic smallpox vaccination program. Smallpox vaccination officially ended in November 1975 in the Netherlands (Manon Haverkate, Personal communication, 5 July 2023), and all participants born before 1976 were assumed to have received smallpox vaccination in the past. Analyses related to immunity among participants were conducted on unweighted data only as the variables used for data weighting consisted of IRFs for mpox.

1 **Table 1:** Eligibility criteria for mpox (monkeypox) vaccination and related covariables included in the analyses.

Eligibility criteria for vaccination against mpox amongst GBMSM				Covariables used in the analyses
Eligibility criteria related to...	Netherlands mpox vaccination program 2022		Derived from risk factors suggested by ECDC [28]	
	General eligibility criteria [23]	Specific eligibility criteria [22]		
HIV-PrEP	People <i>'who use HIV-PrEP or are on the waiting list'</i>	HIV-PrEP usage PrEP waiting list	Use of HIV-PrEP Eligibility for HIV-PrEP	Current use of HIV-PrEP ---
HIV	People who <i>'are HIV-positive with a high risk of STIs'</i>	Living with HIV + regular HCV screening	Not listed	Living with HIV ---
STI-risk	People <i>'known to the sexual health centres (SHC) with a high risk of STIs'</i>	Attending a sexual health centre (SHC)	Not listed	---
		+ partner's notification or + having had an STI diagnosis	Recent history of bacterial sexually transmitted infections	---
Number of sex		or + >3 partners in the last six	Recent history of multiple sex	Number of male sex partners (past 12

partners		months	partners or plans to engage with multiple partners	months) including 0–9, 10–19, and 20 or more.
Specific sexual activities		Not listed	Attending sex on premises venues Group sex practices Chemsex practices	Sex in sex venues and at parties (past two months) Group sex (past two months) Chemsex (past two months)

Results

Sample characteristics

Overall, 2,899 individuals accessed the survey, of whom 2,744 (94.7%) were adult GBMSM 18 years or over living in the Netherlands who provided informed consent to participate in the survey. Of the 2,744 eligible participants, 2,460 (89.7%) completed all questions and were included in the analyses. A comparison of sample characteristics before and after weighting is presented in Table 2. Sample age was slightly higher in the unweighted sample (Median = 42.0 years, IQR 23) than in the weighted sample (Median = 41.0, IQR 24). The weighting reduced the proportional representation of participants living in the Randstad metropolitan area (unweighted sample: 67.4%, weighted sample: 64.3%), and of the proportion of participants who self-identified as gay (unweighted sample: 91.5%, weighted sample: 88.9%). Reductions were also observed in the proportions of participants currently using HIV-PrEP (unweighted sample: 32.5%, weighted sample: 3.8%), living with HIV (unweighted sample: 11.0%, weighted sample: 4.3%), and diagnosed with an STI in the past 12 months (unweighted sample: 23.1%, weighted sample: 12.5%). The proportion of participants with 10–19 sex partners in the past 12 months was also reduced (unweighted sample: 18.4%, weighted sample: 15.0%), as was the proportion of participants with ≥ 20 sex partners in the past 12 months (unweighted sample: 23.9%, weighted sample: 14.3%). Reductions were also observed in the proportions of participants who, in the past two months, engaged in group sex (unweighted sample: 22.3%, weighted sample: 14.6%), chemsex (unweighted sample: 15.3%, weighted sample: 8.5%), or sex in sex venues or at parties (unweighted sample: 21.5%, weighted sample: 14.5%).

24 **Table 2:** Participant characteristics – unweighted and weighted samples

	Unweighted sample ^a	Weighted sample	Differenc ^b	Ratio ^c
	n (%)	%	%	
<i>Sociodemographic characteristics</i>				
Age				
18–29 years	478 (19.4)	25.1	+5.7	1.29
30–39 years	593 (24.1)	22.7	-1.4	0.94
40–49 years	544 (22.1)	19.7	-2.4	0.89
50–59 years	559 (22.7)	20.1	-2.6	0.89
60 or more years	286 (11.6)	12.3	+0.7	1.06
Higher education				
No	428 (17.4)	19.0	+1.6	1.09
Yes	2,032 (82.6)	81.0	-1.6	0.98
Region				
Randstad metropolitan area	1558 (67.4)	64.3	-3.1	0.95
Other regions	802 (32.6)	35.7	+3.1	1.10
Sexual orientation				
Gay	2,250 (91.5)	88.9	-2.6	0.97
Bisexual	180 (7.3)	9.5	+2.2	1.30
Heterosexual	5 (0.2)	0.2	0.0	1.00

Still figuring this out	25 (1.0)	1.4	+0.4	1.40
<i>Eligibility criteria for mpox vaccination</i>				
Currently using HIV-PrEP				
No	1,661 (67.5)	96.2	+28.7	1.43
Yes	799 (32.5)	3.8	-28.7	0.12
STI in past 12 months				
No	1,891 (76.9)	87.5	+10.6	1.14
Yes	569 (23.1)	12.5	-10.6	0.54
Living with HIV				
No	2,190 (89.0)	95.7	+6.7	1.08
Yes	270 (11.0)	4.3	-6.7	0.39
<i>Sexual behaviours</i>				
Number of male sex partners in past 12 months				
0–9	1,419 (57.7)	70.8	+13.1	1.23
10–19	452 (18.4)	15.0	-3.4	0.82
20 or more	589 (23.9)	14.3	-9.6	0.60
Group sex in past 2 months				
No	1,911 (77.7)	85.4	+7.7	1.10
Yes	549 (22.3)	14.6	-7.7	0.65

Chemsex in past 2 months				
No	2,084 (84.7)	91.5	+6.8	1.08
Yes	376 (15.3)	8.5	-6.8	0.56
Sex in sex venues or at parties in past 2 months				
No	1,930 (78.5)	85.5	+7.0	1.09
Yes	530 (21.5)	14.5	-7.0	0.67

25 Note: ^a N=2,460, ^b Weighted estimate minus unweighted estimate, ^c Weighted estimate divided by unweighted estimate.

26 **Rates and covariables of mpox diagnosis**

27 Of the 2,460 participants in the unweighted sample, 73 (3.0%, 95% CI 2.3%–3.6%) reported
28 that they had been diagnosed with mpox (see Table 3). The estimated proportion of mpox
29 diagnoses in the weighted sample was 1.1% (95% CI 0.7% –1.6%).

30 **Table 3:** Rates of mpox diagnosis, invitation to vaccinate against mpox, and mpox vaccination

	Unweighted sample ^a		Weighted sample	Difference ^b	Ratio ^c
	n	% (95% CI)	% (95% CI)		
Mpox diagnosis received	73	3.0 (2.3–3.6)	1.1 (0.7–1.6)	-1.9%	0.37
Invited for mpox vaccination	708	28.8 (27.0–30.6)	13.1 (11.8–14.4)	-15.7%	0.45
At least one dose of mpox vaccine received	485	19.7 (18.1–21.3)	7.8 (6.8–8.9)	-11.9%	0.40

31 Note: ^a N=2;460; ^bWeighted percentage minus unweighted percentage; ^cWeighted percentage divided by unweighted percentage.

32 Results from regression analyses aimed at identifying the covariables of mpox diagnosis are
33 presented in Table 4. In univariable analyses, mpox diagnosis was significantly associated
34 with six potential covariables but not with living with HIV. All seven variables were included
35 in the multivariate model, of which three were removed in the backward estimation (STI
36 diagnosis in the past 12 months, group sex in the past two months and chemsex in the past
37 two months) due to their lack of independent association with mpox diagnosis. In the final
38 multivariable model, mpox diagnosis was significantly independently associated with current
39 use of HIV-PrEP (aOR=3.92, 95% CI 2.01–7.66, $p<.001$) and living with HIV (aOR=2.67,
40 95% CI 1.15–6.22, $p=.023$). An independent association was also found with having had ≥ 20
41 sex partners in the past 12 months (aOR=5.16, 95% CI 2.24–10.68, $p<.001$) but with not
42 having had 10-19 sex partners. Lastly, mpox diagnosis was independently associated with sex
43 in sex venues or at sex parties in the past two months (aOR=2.11, 95% CI 1.26–3.52,
44 $p=.004$). The multivariate model, however, only explained about a fifth of the variance in the
45 risk of mpox diagnoses (Nagelkerke R-squared=0.18).

46 **Table 4:** Covariates of mpox diagnosis and mpox vaccination^a.

	Recent mpox diagnosis					Recent mpox vaccination				
	Rate	Univariable		Multivariable		Rate	Univariable		Multivariable	
		analyses		analysis			analyses		analysis	
	n (%)	OR	p-value	aOR	p-value	n/N (%)	OR	p-value	aOR	p-value
	(95% CI)		(95% CI)			(95% CI)		(95% CI)		
Current HIV-PrEP use										
No	22/1,661 (1.3)	Ref.		Ref.		127/1,661 (7.6)	Ref.		Ref.	
Yes	51/799 (6.4)	5.08	<.001	3.92	<.001	358/799 (44.8)	9.81	<.001	8.84	<.001
		(3.06–		(2.01–			(7.80–		(6.71–	
		8.44)		7.66)			12.32)		11.66)	
Living with HIV										
No	62/2,190 (2.8)	Ref.		Ref.		439/2,190 (20.0)	Ref.		Ref.	
Yes	11/270 (4.1)	1.46	.259	2.67	.023	46/270 (17.0)	.82	.242	2.43	<.001
		(.76–		(1.15–			(.59–		(1.63–	

		2.80)		6.22)			1.14)		3.60)	
STI diagnosis ^b										
No	36/1,891 (1.9)	Ref.		---		260/1,891 (13.7)	Ref.			
Yes	37/569 (6.5)	3.58	p<.001	---	---	225/569 (39.5)	4.10	<.001	1.86	<.001
		(2.24–					(3.32–		(1.45–	
		5.73)					5.08)		2.39)	
Number of sex partners ^b										
0-9	11/1419 (0.8)	Ref.		Ref.		158/1419 (11.1)	Ref.		Ref.	
10-19	12/452 (2.7)	3.49		1.98	.118	124/542 (27.4)	3.02	<.001	1.54	.005
		(1.53–		(.84–			(2.32–		(1.14–	
		7.97)		4.66)			3.93)		2.08)	
20 or more	50/589 (8.5)	11.87	<.001	5.16	<.001	203/589 (34.5)	4.20	<.001	1.65	<.001
		(6.14–		(2.24–			(3.31–		(1.252.1	
		22.98)		10.68)			5.32)		8)	
Group sex ^c										

No	36/1,911 (1.9)			---		309/1,911 (16.2)			---	
Yes	37/549 (6.7)	3.76	<.001	---	---	176/549 (32.1)	2.45	<.001	---	---
		(2.35–					(1.9–			
		6.02)					3.04)			
Chemsex ^c										
No	46/2,084 (2.2)			---		357/2084 (17.1)			---	
Yes	27/376 (7.2)	3.43	<.001	---	---	128/376 (34.0)	2.50	<.001	---	---
		(2.10–					(1.96–			
		5.59)					3.18)			
Sex in venues or at parties ^c										
No	32/1,930 (1.7)					329/1,930 (17.0)				
Yes	41/530 (7.7)	4.97	<.001	2.11	.004	156/530 (29.4)	2.03	<.001	---	---
		(3.10–		(1.26–			(1.63–			
		7.98)		3.52)			2.53)			

47 Note: ^a N=2,460; non-weighted sample only, ^b In the past 12 months, ^c In the past two months.

48 **Rates and covariables of mpox vaccination**

49 Of the 2,460 participants in the unweighted sample, 708 (28.8%, 95% CI 27.0%–30.6%) had
50 received an invitation to vaccinate against mpox, and 485 (19.7%, 95% CI 18.1%–21.3%)
51 had received (initial) mpox vaccination (see Table 3). In the weighted sample, 13.1% (95%
52 CI 11.8%–14.4%) had received an invitation for mpox vaccination, and 7.8% (95% CI 6.8%–
53 8.9%) had received (initial) mpox vaccination.

54

55 In univariable analyses, (initial) mpox vaccination was significantly associated with all
56 potential covariables, except living with HIV (see Table 4). The backward procedure resulted
57 in the elimination of three out of the seven terms from the model (group sex in the past two
58 months, chemsex in the past two months and sex in sex venues or at sex parties in the past
59 two months) due to their lack of independent association with mpox diagnosis. In the final
60 multivariable model, mpox vaccination was significantly independently associated with
61 current HIV-PrEP use (aOR=8.84, 95% CI 6.71–11.66, $p<.001$), living with HIV (aOR=2.43,
62 95% CI 1.63–3.60, $p<.001$), an STI diagnosis in the past 12 months (aOR=1.86, 95% CI
63 1.45–2.39, $p<.001$), having had 10-19 sex partners in the past 12 months (aOR=1.54, 95% CI
64 1.14–2.08, $p=.005$) and having had ≥ 20 sex partners in the past 12 months (aOR=1.65, 95%
65 CI 1.25–2.18, $p<.001$). The multivariate model explained nearly a third of the variance in the
66 uptake of mpox vaccination (Nagelkerke R-squared =.030).

67

68 **Proportion of the GBMSM subpopulation most at risk of mpox**

69 The proportion of participants reporting zero, one, two or three IRFs for mpox diagnosis (i.e.,
70 current HIV-PrEP use or living with HIV, ≥ 20 sex partners in the past 12 months, or sex in
71 sex venues or at parties in the past two months) is shown in Table 5.

72 Of the 2,460 participants in the non-weighted sample, 1,104 (44.9%, 95% CI 42.9%–46.8%)
73 presented no IRF, 746 (30.3%, 95% CI 28.5%–32.1%) presented one IRF, 392 (15.9%, 95%
74 CI 14.5%–17.4%) two IRFs, and 218 (8.9%, 95% CI 7.7%–10.0%) three IRFs (Table 5). In
75 the weighted sample, these proportions were 72.8% (95% CI 71.0%–74.6%), 19.3% (95% CI
76 17.7%–20.8%), 6.3% (95% CI 5.3%–7.2%), and 1.6% (95% CI 1.1%–2.1%), respectively.
77 In total, 1,356 of the 2,460 participants in the non-weighted sample (55.1%, 95% CI 53.2%–
78 57.1%) presented at least one of the four IRFs for mpox diagnosis. This proportion was
79 smaller (27.2%, 95% CI 25.4%–29.0%) in the weighted sample.

80 **Table 5:** Proportions of GBMSM presenting independent risk factors for mpox diagnosis.

Number of independent risk factors for mpox diagnosis ^a	Unweighted sample ^b		Weighted sample
	n	% (95% CI)	% (95% CI)
None	1,104	44.9 (42.9–46.8)	72.8 (71.0–74.6)
One or more	1,356	55.1 (53.2–57.1)	27.2 (25.4–29.0)
<i>One</i>	746	30.3 (28.5–32.1)	19.3 (17.7–20.8)
<i>Two</i>	392	15.9 (14.5–17.4)	6.3 (5.3–7.2)
<i>Three</i>	218	8.9 (7.7–10.0)	1.6 (1.1–2.1)

81 Note: ^a Four independent risk factors for mpox diagnosis were identified in this study: current HIV-PrEP use, living with HIV, 20+ sex partners
 82 in the past 12 months, or sex in sex venues or at sex parties in the past two months. The number of independent risk factors accumulated by
 83 participants ranged from 0 to 3, as the first two factors (current HIV-PrEP use and living with HIV) are mutually exclusive. ^b N=2,460.

84 **Immunity among most-at-risk GBMSM**

85 Of the 1,356 participants with one or more IRFs in the unweighted sample, 61 (4.5%, 95%
86 CI 3.4%–5.6%) had been diagnosed with mpox, 181 (13.3%, 95% CI 11.5%–15.2%) had
87 presumably received one dose of mpox vaccine while being vaccinated against smallpox, and
88 251 (18.5, 95% CI 16.4%–20.6%) had presumably received one dose of mpox vaccine but no
89 smallpox vaccination (Table 6). Based on the proportions of participants reporting the first
90 two situations, 17.8% (95% CI 15.8%–19.9%) of the 1,356 participants with one or more
91 IRFs, would have presumably achieved a satisfactory immunity against mpox. The overall
92 proportion of satisfactory immunity varied according to the number of independent risk
93 factors reported, from 12.5% (95% CI 10.1%–14.8%) of the 746 participants with one IRF,
94 20.4% (95% CI 16.4%–24.4%) of the 392 participants with two IRFs and 31.7% (95% CI
95 25.4%–37.9%) of the 218 participants with three IRFs.

96 **Table 6:** Level of immunity towards mpox according to GBMSM's numbers of independent risk factors for mpox diagnosis (unweighted data ^a)

Number of independent risk factors for mpox diagnosis ^a	n	Mpox diagnosis		Mpox vaccination ^b and smallpox vaccination ^c		Mpox vaccination ^b and no smallpox vaccination ^c		No mpox diagnosis nor mpox vaccination	
		n	% (95% CI)	n	% (95% CI)	n	% (95% CI)	n	% (95% CI)
None	1,104	3	0.3 (0.0–0.6)	12	1.1 (0.5–1.7)	41	3.7 (2.6–4.8)	1,048	94.9 (93.6–96.2)
One or more	1,356	61	4.5 (3.4–5.6)	181	13.3 (11.5–15.2)	251	18.5 (16.4–20.6)	863	63.6 (61.1–66.2)
<i>One</i>	746	13	1.7 (0.8–2.7)	80	10.7 (8.5–13.0)	114	15.3 (12.7–17.9)	539	72.3 (69.0–74.7)
<i>Two</i>	392	18	4.6 (2.5–6.7)	62	15.8 (12.2–19.4)	84	21.4 (17.4–18.3)	228	58.2 (53.3–59.1)
<i>Three</i>	218	30	13.8 (9.2–18.4)	39	17.9 (12.8–23.0)	53	24.3 (18.6–30.1)	96	44.0 (34.7–50.7)

97 Note: ^a N=2,460. ^b Due to the timing of the survey, we assumed that all GBMSM reporting mpox vaccination had only received one dose of
98 vaccine. ^c All participants born before 1976 were assumed to have received smallpox vaccination.

99

Discussion

100 Our findings provide novel insights into the extent and covariables of the risk of mpox
101 diagnosis as well as the uptake and need of mpox vaccination among GBMSM in the
102 Netherlands. Of the participants in this study, 3.0% had been diagnosed with mpox and a fifth
103 (19.7%) had received (initial) mpox vaccination since the start of the mpox outbreak. Using
104 data weighting to attenuate participation bias, we found that an estimated 1.1% of the
105 sexually active GBMSM population 18-80 years in the Netherlands had been diagnosed with
106 mpox and less than a tenth (7.8%) had received (initial) mpox vaccination. Our estimates
107 seem to surpass those derived from the national records of mpox cases and first dose mpox
108 vaccination at the time the survey recruitment ended. By September 1st, 2022, 1,080
109 GBMSM mpox cases [11] and 12,820 first vaccine doses [29] had been recorded nationally.
110 Extrapolating these figures to a population of 310,000 GBMSM yields a mpox prevalence
111 estimate of 0.3% and a vaccination prevalence estimate of 4.1%.

112

113 Our multivariable assessment of covariables found commonalities and differences in the
114 independent covariables of mpox diagnosis and mpox vaccination. Mpox diagnosis and mpox
115 vaccination were each independently associated with HIV-PrEP use, living with HIV and
116 reporting ≥ 20 sex partners in the past 12 months. STI diagnosis in the past 12 months and 10–
117 19 partners in the past 12 months were independently associated with mpox vaccination but
118 not with mpox diagnosis. Sex in sex venues or at parties in the past two months was
119 independently associated with mpox diagnosis but not with mpox vaccination. Neither group
120 sex nor chemsex in the past two months were independently associated with mpox diagnosis
121 or vaccination, although associations were observed in univariable analyses.

122

123 In settings with limited mpox vaccine availability, mpox vaccination is best targeted at
124 GBMSM most at risk for mpox, as also recommended by ECDC [28], and our findings
125 provide novel guidance to further improve the alignment between the eligibility criteria for
126 mpox vaccination and the evidence regarding risk factors for mpox. Our findings underscore
127 the importance of four IRFs for mpox diagnosis: current use of HIV-PrEP, living with HIV, a
128 higher number (≥ 20) of sex partners in the past 12 months, and having sex in sex venues or
129 at sex parties in the past 2 months.

130

131 These findings confirm the importance of HIV-PrEP use as an eligibility criterion for mpox
132 vaccination among GBMSM in the Netherlands [22], and more broadly in Europe [28]. Our
133 results also suggest the importance of maintaining living with HIV as eligibility criterion in
134 the Netherlands [22], although this was not listed by ECDC [28]. The findings also provide
135 new insights into the ways in which sexual activity affects GBMSM's vulnerability to mpox.
136 The finding that both a high number of sex partners and having sex in sex venues or parties
137 were independently associated with mpox diagnosis is noteworthy. This suggests that
138 GBMSM's susceptibility to mpox does not merely result from their number of sex partners
139 (and sex contacts) but also from engaging in specific sexual activities and networks.

140

141 The findings on IRF for mpox diagnosis can help refine the eligibility criteria for mpox
142 vaccination, starting with the criteria used in the Netherlands. Having multiple sex partners
143 was noted as a potential risk factor for mpox in ECDC guidance [28]. During the 2022
144 vaccination campaign in the Netherlands, the number of partners was not used as a primary
145 eligibility criteria. However, GBMSM known from the sexual health centres as being at
146 higher risk of STIs had to have more than 3 partners in the last 6 months to be invited for
147 vaccination [22]. In light of our results on the number of partners from which the risk for

148 mpox become significantly higher, the threshold of three partners per semester seems
149 relatively low. In the context of limited vaccine stock, we suggest using ≥ 10 partners in the
150 past 6 months as an independent eligibility criterion for vaccinating most at risk GBMSM in
151 the Netherlands. This criterion derives from an adaptation of the ≥ 20 partners threshold
152 established in this study to the 6-month timeframe used for the recording national indicator
153 data.

154

155 Our findings also confirm ECDC guidance that attending sex venues is a risk factor for mpox
156 [28], and this should be included as an eligibility criterion for mpox vaccination among
157 GBMSM in the Netherlands. However, unlike suggested by ECDC [28], we did not find that
158 engaging in group sex, chemsex, or having a recent history of STI were independent risk
159 factors for mpox. Nevertheless, as these variables were associated with mpox diagnosis in
160 univariate analyses, they could potentially offer additional insights in determining the need
161 for mpox vaccination, particularly when data concerning other eligibility criteria, such as
162 having sex at sex venues or parties, are not available.

163

164 Our assessment enabled estimating the proportions of GBMSM most at risk for mpox and in
165 need of vaccination. In the non-weighted sample, more than half of the participants (55.1%)
166 presented at least one of the four IRFs for mpox. This proportion was reduced to over a
167 quarter (27.2%) in the weighted sample, equating to approximately 83,700 individuals when
168 extrapolated to an estimated 310,000 adult GBMSM.

169

170 As the number of IRFs accumulated increased, the size of the high-risk groups decreased.
171 Specifically, the presumed core transmission group, consisting in this study of GBMSM with
172 three IRFs, accounted for less than a tenth (8.9%) of participants in the non-weighted sample

173 and less than 2% (1.6%) in the weighted sample. The study also contributed to estimating the
174 proportion of GBMSM at higher risk who had achieved a satisfactory level of immunity
175 towards mpox at the time of the survey. Among the participants with one or more IRFs, less
176 than one in five (17.8%) had satisfactory immunity either due to infection or vaccination. The
177 proportion of satisfactory immunity varied according to the number of IRFs reported, from
178 above a tenth (12.5%) among participants with one IRF, to a fifth (20.4%) among participants
179 with two IRFs and near a third (31.7%) among participants with three IRFs. If all GBMSM
180 born after 1975, who have not been vaccinated against smallpox but had presumably received
181 only one dose of mpox vaccine were to receive a second dose — acknowledging the
182 challenges of achieving full compliance with the recommendation to obtaining two doses —
183 the resultant immunity levels would approximate 27.8%, 41.8%, and 56% among GBMSM
184 with one, two, and three IRFs for mpox, respectively.

185

186 These findings show that the level of immunity against mpox achieved at the time of the
187 survey and potentially achieved if second doses are received after the time of the survey, was
188 highest amongst GBMSM reporting three IRFs. As modelling has shown [15], a vaccination
189 strategy targeting those most at risk may contribute to effectively curbing mpox outbreaks. It
190 is, however, possible that mpox is reintroduced among lower risk and less vaccinated and
191 immune GBMSM, for instance those who present one or two IRFs for mpox. Vaccination of
192 at least all GBMSM at risk presenting one or more IRFs is hence needed [21].

193

194 This study has unique strengths. To the best of our knowledge, this is the first study to assess
195 the extent of mpox diagnoses and vaccination in a community sample of GBMSM, and to
196 assess and compare commonalities and differences in covariables for mpox diagnosis and
197 mpox vaccination. Also, we recruited a large sample of GBMSM and achieved a high survey

198 completion rate. Furthermore, we provided an updated estimate of the size of the sexually
199 active adult GBMSM population in the Netherlands and used weighting procedures to reduce
200 some recruitment biases. Our study also has limitations that are common to survey research
201 in GBMSM, including potential memory and social desirability biases related to self-report.
202 We mitigated these biases by clearly specifying reporting periods and ensuring anonymity of
203 responses. Furthermore, we used convenience sampling and, despite the use of weighting
204 procedures, the findings may not be representative of the population of GBMSM in the
205 Netherlands. The survey's focus may have led to an overrepresentation of GBMSM interested
206 in mpox, including individuals who had mpox or had obtained vaccination. Furthermore, as
207 mpox is a relatively rare condition, the number of participants diagnosed with mpox was
208 limited, despite the large sample size. This low number led to the risk of not being able to
209 detect associations with covariables of mpox diagnosis. Our analyses on covariables of mpox
210 diagnosis would therefore need to be replicated in a sample that includes a larger number of
211 participants diagnosed with mpox, including people living with HIV.

212

213 Also, some information on specific eligibility criteria for mpox vaccination was not assessed
214 in the survey, notably being on a waiting list for PrEP and regular HCV screening among
215 participants living with HIV. In addition, the survey did not allow for differentiating between
216 vaccination pre- or post-exposure to mpox, albeit that uptake of post-exposure vaccinations
217 remains very limited in the Netherlands. Furthermore, the survey assessed mpox diagnoses
218 and vaccination uptake and covariables only during August 2022, which was merely one
219 month into the vaccination program. However, while the reach of the vaccination program
220 has increased thereafter, vaccinations mostly occurred at the start of the program, and
221 GBMSM at highest risk for mpox were invited first.

222

223 The prospect of mpox reintroduction from endemic regions remains a possibility, carrying
224 with it the potential for novel mpox outbreaks. To prevent future reintroductions from giving
225 rise to new outbreaks, and to ensure the sustained eradication of mpox [18], even in the
226 absence of such introductions, the vaccination of all GBMSM, and any other groups at risk
227 for mpox, may prove necessary. However, the comprehensive vaccination of entire groups or
228 populations can be constrained by factors such as limited vaccine availability, lack of
229 (human) resources, or a little enthusiasm for mpox vaccination among the targeted groups or
230 population. In situations where universal vaccination is not feasible, our research findings
231 play a crucial role in determining individuals most susceptible to mpox, thereby offering a
232 targeted approach to mpox vaccination.

233

234 The findings of our study underscore the importance of an evidence-based approach to
235 identifying risk factors for mpox diagnosis and guiding the selection of eligibility criteria for
236 mpox vaccination. Our approach has already contributed to a refinement of vaccination
237 eligibility criteria applied as of May 2023 in the Netherlands [16]. Both ≥ 10 partners in the
238 past six months and having sex at sex venues or parties were added to the list of eligibility
239 criteria [16]. Our findings have also contributed to the policy change to provide access to
240 vaccination to a larger number of GBMSM than initially planned [30]. As of May 2023,
241 unvaccinated GBMSM who self-identify as high-risk for mpox and GBMSM born after 1975
242 who received only a single vaccine dose have the possibility to contact their healthcare
243 service to discuss mpox vaccination[16]. This extension of the scope of the vaccination
244 program will provide valuable health benefits to a larger group of GBMSM at risk of mpox.

245 **Funding:** The National Institute for Public Health and the Environment (RIVM) and Soa
246 Aids Nederland provided financial support for this research study.

247

248 **Data availability:** Data are available from the corresponding author upon reasonable request.

249

250 **Acknowledgements:** The authors thank Manon Haverkate, Lisette Kuyper, and Hanneke de
251 Graaf for sharing information and insights, Arjan van Bijnen and Laurian Kuipers for their
252 contribution to the recruitment, and all participants to the survey.

253

254 **Conflict of interest:** None.

255

256 **Authors' contributions:** PA developed the idea for this study, conducted the statistical
257 analyses, and wrote the first draft of the manuscript together with JdW. EOdc and MX
258 provided important additions to the manuscript, including information and insights on the
259 mpox outbreak and vaccination program in the Netherlands. PZ, HB, CB, IK, SD, and MtW
260 reviewed the manuscript and contributed further revisions. All authors have read the final
261 manuscript and accepted authorship.

262 **References**

- 263 1. World Health Organization [Internet]. Geneva: World Health Organization; c2023.
264 WHO recommends new name for monkeypox disease; 2022 Nov 28 [cited 2023 Feb 23];
265 about 4 screens. Available from: [https://www.who.int/news/item/28-11-2022-who-](https://www.who.int/news/item/28-11-2022-who-recommends-new-name-for-monkeypox-disease)
266 [recommends-new-name-for-monkeypox-disease](https://www.who.int/news/item/28-11-2022-who-recommends-new-name-for-monkeypox-disease)
- 267 2. Marennikova SS, Šeluhina, EM, Mal'ceva NN, Čimiškjan KL, Macevič GR. Isolation
268 and properties of the causal agent of a new variola-like disease (monkeypox) in man.
269 Bull. World Health Organ. 1972;46(5):599–611.
- 270 3. Sukhdeo S, Mishra S, Walmsley S. Human monkeypox: a comparison of the
271 characteristics of the new epidemic to the endemic disease. BMC Infect Dis.
272 2022;22(1):928. <https://doi.org/10.1186/s12879-022-07900-7>
- 273 4. Bunge EM, Hoet B, Chen L, Lienert F, Weidenthaler H, Baer LR, Steffen R. The
274 changing epidemiology of human monkeypox-A potential threat? A systematic review.
275 PLoS Negl Trop Dis. 2022;16(2):e0010141.
276 <https://doi.org/10.1371/journal.pntd.0010141>
- 277 5. Vivancos R, Anderson C, Blomquist P, Balasegaram S, Bell A, Bishop L, et al.
278 Community transmission of monkeypox in the United Kingdom, April to May 2022.
279 Euro Surveill. 2022;27(22):2200422. [https://doi.org/10.2807/1560-](https://doi.org/10.2807/1560-7917.ES.2022.27.22.2200422)
280 [7917.ES.2022.27.22.2200422](https://doi.org/10.2807/1560-7917.ES.2022.27.22.2200422)
- 281 6. Thornhill JP, Barkati S, Walmsley S, Rockstroh J, Antinori A, Harrison LB, et al.
282 Monkeypox virus infection in humans across 16 countries - April-June 2022. N Engl J
283 Med. 2022;387(8):679-691. <https://doi.org/10.1056/NEJMoa2207323>

- 284 7. Vaughan AM, Cenciarelli O, Colombe S, Alves de Sousa L, Fischer N, Gossner CM, et
285 al. A large multi-country outbreak of monkeypox across 41 countries in the WHO
286 European Region, 7 March to 23 August 2022. *Euro Surveill.* 2022;27(36):2200620.
287 <https://doi.org/0.2807/1560-7917.ES.2022.27.36.2200620>
- 288 8. World Health Organization [Internet]. Geneva: World Health Organization; c2023. 2022-
289 23 Mpox (Monkeypox) outbreak: Global trends; 2023 Feb 21 [cited 2023 Feb 23]; [about
290 25 screens]. Available from: [https://worldhealthorg.shinyapps.io/mpx_global/#section-](https://worldhealthorg.shinyapps.io/mpx_global/#section-fns)
291 [fns](https://worldhealthorg.shinyapps.io/mpx_global/#section-fns)
- 292 9. Selb R, Werber D, Falkenhorst G, Steffen G, Lachmann R, Ruscher C, et al. A shift from
293 travel-associated cases to autochthonous transmission with Berlin as epicentre of the
294 monkeypox outbreak in Germany, May to June 2022. *Euro Surveill.*
295 2022;27(27):2200499. <https://doi.org/10.2807/1560-7917.ES.2022.27.27.2200499>
- 296 10. Vusirikala A, Charles H, Balasegaram S, Macdonald N, Kumar D, Barker-Burnside C, et
297 al. Epidemiology of early monkeypox virus transmission in sexual networks of gay and
298 bisexual men, England, 2022. *Emerg Infect Dis.* 2022;28(10):2082-2086.
299 <https://doi.org/10.3201/eid2810.220960>
- 300 11. Van Ewijk C, Miura F, van Rijckevorsel G, de Vries H, Welkers M, and van den Berg O,
301 et al. (2023). Mpox outbreak in the Netherlands, 2022: public health response,
302 characteristics of the first 1,000 cases and protection of the first-generation smallpox
303 vaccine. *Eurosurveillance*, 28, 2200772, [https://doi.org/10.2807/1560-](https://doi.org/10.2807/1560-7917.ES.2023.28.12.2200772)
304 [7917.ES.2023.28.12.2200772](https://doi.org/10.2807/1560-7917.ES.2023.28.12.2200772)
- 305 12. Payne AB, Ray LC, Kugeler KJ, Fothergill A, White EB, Canning M, et al. Incidence of
306 monkeypox among unvaccinated persons compared with persons receiving ≥ 1

307 JYNNEOS vaccine dose — 32 U.S. jurisdictions, July 31–September 3, 2022. *Morb*
308 *Mortal Wkly Rep* 2022;71:1278-1282. <http://dx.doi.org/10.15585/mmwr.mm7140e3>.

309 13. World Health Organization. Vaccines and immunisation for monkeypox. Interim
310 guidance 16 November 2022. Geneva: World Health Organization; 2022 Nov 20p.

311 14. Martín-Delgado MC, Martín Sánchez FJ, Martínez-Sellés M, Molero García JM, Moreno
312 Guillén S, Rodríguez-Artalejo FJ, et al. Monkeypox in humans: a new outbreak. *Rev Esp*
313 *Quimioter*. 2022;35(6):509-518. <https://doi.org/10.37201/req/059.2022>

314 15. Knight J, Tan DHS, Mishra S. Maximising the impact of limited vaccine supply under
315 different early epidemic conditions: a 2-city modelling analysis of monkeypox virus
316 transmission among men who have sex with men. *CMAJ*. 2022;194(46):E1560-E1567.
317 <https://doi.org/10.1503/cmaj.221232>

318 16. National Institute for Public Health and the Environment [Internet]. Bilthoven, the
319 Netherlands: National Institute for Public Health and the Environment. Mpox infections;
320 2023 Feb 16 [cited 2023 Feb 24]; [about 8 screens]. Available from:
321 <https://www.rivm.nl/en/monkeypox>

322 17. Statistics Netherlands [Internet]. Den Haag, the Netherlands: Statistics Netherlands
323 c2023. Population dashboard. Up to date figures on the Dutch population; 2023 Feb 24
324 [cited 2023 Feb 24]; [about 3 screens]. Available from: [https://www.cbs.nl/en-](https://www.cbs.nl/en-gb/visualisations/dashboard-population)
325 [gb/visualisations/dashboard-population](https://www.cbs.nl/en-gb/visualisations/dashboard-population)

326 18. European Centre for Disease Prevention and Control [Internet]. Stockholm, Sweden:
327 European Centre for Disease Prevention and Control c2023. Mpox (formerly named
328 monkeypox) situation update, as of 14 February 2023; 2023 Feb 15 [cited 2023 Feb 24].
329 Available from: [https://www.ecdc.europa.eu/en/news-events/monkeypox-situation-](https://www.ecdc.europa.eu/en/news-events/monkeypox-situation-update)
330 [update](https://www.ecdc.europa.eu/en/news-events/monkeypox-situation-update)

- 331 19. World Health Organization [Internet]. Geneva: World Health Organization; d2023. An
332 mpox resurgence in the European Region this spring and summer? To prevent that, key
333 measures must continue; 2023 May 2023 [cited 2023 Aug 24]; [1 screens]. Available
334 from [https://www.who.int/europe/news/item/17-05-2023-an-mpox-resurgence-in-the-](https://www.who.int/europe/news/item/17-05-2023-an-mpox-resurgence-in-the-european-region-this-spring-and-summer--to-prevent-that--key-measures-must-continue)
335 [european-region-this-spring-and-summer--to-prevent-that--key-measures-must-continue](https://www.who.int/europe/news/item/17-05-2023-an-mpox-resurgence-in-the-european-region-this-spring-and-summer--to-prevent-that--key-measures-must-continue)
- 336 20. Xiridou M, Miura F, Adam P, Op de Coul E, de Wit J, Wallinga J. The fading of the
337 mpox outbreak among men who have sex with men: a mathematical modelling study.
338 Preprint medRxiv available online on June 20, 2023.
339 <https://www.medrxiv.org/content/10.1101/2023.01.31.23285294v3>
- 340 21. World Health Organization [Internet]. Geneva: World Health Organization; c2023.
341 Mpox – It hasn't gone away; 2023 Feb 15 [cited 2023 Feb 24]; [about 6 screens].
342 Available from: [https://www.who.int/europe/news/item/15-02-2023-as-the-mpox--](https://www.who.int/europe/news/item/15-02-2023-as-the-mpox--emergency--continues--the-united-kingdom-shows-how-achieving-and-sustaining-disease-elimination-has-to-be-the-next-priority)
343 [emergency--continues--the-united-kingdom-shows-how-achieving-and-sustaining-](https://www.who.int/europe/news/item/15-02-2023-as-the-mpox--emergency--continues--the-united-kingdom-shows-how-achieving-and-sustaining-disease-elimination-has-to-be-the-next-priority)
344 [disease-elimination-has-to-be-the-next-priority](https://www.who.int/europe/news/item/15-02-2023-as-the-mpox--emergency--continues--the-united-kingdom-shows-how-achieving-and-sustaining-disease-elimination-has-to-be-the-next-priority)
- 345 22. Rijksinstituut voor Volksgezondheid en Milieu [National Institute for Public Health and
346 the Environment] [Internet]. Bilthoven, the Netherlands: Rijksinstituut voor
347 Volksgezondheid en Milieu. Mpoxvaccinatie Uitvoeringsrichtlijn [mpox vaccination
348 guidelines] [about 29 screens]. Dutch. Available from:
349 <https://lci.rivm.nl/richtlijnen/monkeypoxvaccinatie#1-over-deze-richtlijn>
- 350 23. Leenstra T. (Landelijke Coördinatie Infectieziektebestrijding, Rijksinstituut voor
351 Volksgezondheid en Mileau [National Coordination Centre for Communicable Disease
352 Control, National Institute for Public Health and the Environment]). Letter to: Marjolein
353 Sonnemaa (Ministerie van Volksgezondheid, Welzijn en Sport [Ministry of Health,
354 Welfare and Sport]). 2022 Jul 6. 5p. Dutch. Available from:

- 355 [https://open.overheid.nl/repository/ronl-](https://open.overheid.nl/repository/ronl-614a46ff6591d770978a2bae54768ae183cd7468/1/pdf/adviesbrief-mpx-prep-vaccinatie-6-juli-2022.pdf)
- 356 [614a46ff6591d770978a2bae54768ae183cd7468/1/pdf/adviesbrief-mpx-prep-vaccinatie-](https://open.overheid.nl/repository/ronl-614a46ff6591d770978a2bae54768ae183cd7468/1/pdf/adviesbrief-mpx-prep-vaccinatie-6-juli-2022.pdf)
- 357 [6-juli-2022.pdf](https://open.overheid.nl/repository/ronl-614a46ff6591d770978a2bae54768ae183cd7468/1/pdf/adviesbrief-mpx-prep-vaccinatie-6-juli-2022.pdf)
- 358 24. Van Sighem A., Rokx C, Op de Coul E. HIV in the Netherlands. In: van Sighem A, Wit
- 359 F, Boyd A, Smit C, Matser A, van de Valk M. Human Immunodeficiency Virus (HIV)
- 360 Infection in the Netherlands. Monitoring Report 2022. Amsterdam, the Netherlands:
- 361 Stichting hiv monitoring; 2023. p. 11-92. Available from: [https://www.hiv-](https://www.hiv-monitoring.nl/en/resources/monitoring-report-2022)
- 362 [monitoring.nl/en/resources/monitoring-report-2022](https://www.hiv-monitoring.nl/en/resources/monitoring-report-2022)
- 363 25. Op de Coul EL, Schreuder I, Conti S, van Sighem A, Xiridou M, Van Veen MG, et al.
- 364 Changing patterns of undiagnosed HIV infection in the Netherlands: Who benefits most
- 365 from intensified HIV test and treat policies? PLoS One. 2015;10(7): e0133232.
- 366 <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0133232>
- 367 26. Kuyper L. Seksualiteit en seksuele gezondheid bij homo- en biseksuelen. [Sexuality and
- 368 sexual health of gay and bisexual persons.] In: Bakker F, & Vanwesenbeeck I, editors.
- 369 Seksuele gezondheid in Nederland 2006. Delft, the Netherlands: Eburon; 2006. pp. 167-
- 370 188. Dutch. Available from: <https://shop.rutgers.nl/651860.pdf>
- 371 27. Statistics Netherlands [Internet]. Den Haag, the Netherlands: Statistics Netherlands
- 372 c2023. Population growth. How fast is the population of the Netherlands growing?; not
- 373 dated [cited 2023 Feb 24]; [about 2 screens]. Available from: [https://www.cbs.nl/en-](https://www.cbs.nl/en-gb/visualisations/dashboard-population/population-dynamics/population-growth)
- 374 [gb/visualisations/dashboard-population/population-dynamics/population-growth](https://www.cbs.nl/en-gb/visualisations/dashboard-population/population-dynamics/population-growth)
- 375 28. European Centre for Disease Prevention and Control. Monkeypox multi-country
- 376 outbreak – second update, 18 October 2022. ECDC: Stockholm; 2022.
- 377 [https://www.ecdc.europa.eu/en/publications-data/monkeypox-multi-country-outbreak-](https://www.ecdc.europa.eu/en/publications-data/monkeypox-multi-country-outbreak-second-update)
- 378 [second-update](https://www.ecdc.europa.eu/en/publications-data/monkeypox-multi-country-outbreak-second-update)

379 29. National Institute for Public Health and the Environment (2022). Bilthoven, the
380 Netherlands: National record of mpox vaccination [Osiris and iMPeX databases].
381 Unpublished raw data.

382 30. Van Dissel JT. (Centrum Infectieziektebestrijding, Rijksinstituut voor Volksgezondheid
383 en Mileu [Centre for Infectious Disease Control, National Institute for Public Health and
384 the Environment]). Letter to: Marjolein Sonnema (Ministerie van Volksgezondheid,
385 Welzijn en Sport [Ministry of Health, Welfare and Sport]). 2022 Nov 29. 11p. Dutch.
386 Available from: [https://open.overheid.nl/Details/ronl-
b7a448c0a585892110380aa55cb35a558e75b34f/1](https://open.overheid.nl/Details/ronl-
387 b7a448c0a585892110380aa55cb35a558e75b34f/1)